Montiget is generally well tolerated. However, as with any other drug, it may cause some adverse events. Montiget Side Effects are usually mild and do not require discontinuation of therapy.
Montiget Side Effects (Hypersensitivity Reactions)
- urticaria and very rarely, hepatic eosinophilic infiltration
Side Effects of Montiget on Gastro-Intestinal Tract
- Abdominal pain
Other Side Effects Include;
Dream abnormalities, hallucinations, palpitations, drowsiness, irritability, restlessness, insomnia, increased sweating, headache, myalgia including muscle cramps, increased bleeding tendency, bruising edema, tremor, dry mouth, vertigo and arthralgia.
Montiget is contraindicated in a patient who has shown hypersensitivity to the montelukast or any of its components. Montiget is not indicated for use in acute asthma attacks including status asthmaticus.
- Montiget should not be abruptly substituted for inhaled or oral corticosteroids. However the dose of inhaled corticosteroid may be reduced gradually under medical supervision.
- Although a causal relationship with leukotriene receptor antagonism has not been established, caution and appropriate clinical monitoring is recommended when systemic corticosteroid reduction is considered in patient receiving Montiget.
- Montiget should not be used as monotherapy for the treatment and management of exercise-induced asthma. Patients who have exacerbations of asthma after exercise should continue to use their usual regimen of inhaled β-agonists as prophylaxis and should have it available as and when required.
- Montiget does not block Broncho-constrictor response to aspirin or non-steroidal anti-inflammatory drugs in aspirin sensitive asthmatic patients. Such patients should continue to avoid aspirin and other non-steroidal anti-inflammatory drugs e.g. Phlogin
- Caution should be exercised when using Montiget with bronchodilator therapy. When clinical response is apparent the bronchodilator therapy should be reduced.
Montiget – Use in Pregnancy and Lactation
Montelukast sodium has not been studied in pregnant women. It should be used during pregnancy only if clearly needed. Moreover, it is not known if montelukast sodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Montiget is given to a nursing mother.
It is recommended that clinical monitoring, particularly in children, be conducted when potent hepatic enzyme inducers such as phenytoin, phenobarbital, or rifampicin are given with montelukast sodium. No dosage adjustment for Montiget is recommended.